Joseph Gharios
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Joseph Gharios has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Ghassan Chakhtoura
Digestive Surgery Department, Hôtel-Dieu de France Hospital, Faculty of Medicine Saint Joseph University, Beirut, Lebanon
3 shared publications- Roger Noun
Digestive Surgery Department Beirut 1100 Faculty of Medicine, Saint Joseph University of Beirut
2 shared publications - Sébastien Gaujoux
Department of Hepatobiliary and Pancreatic Surgery and Liver Transplantation, AP-HP Pitié-Salpêtrière Hospital, Paris, France
2 shared publications Benoit Terris
Facultéde Médecine Paris Descartes, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
1 shared publicationCarla Tohmé-Noun
Department of Imaging, Clinique du Levant, University Saint Joseph Medical School, Beirut 50226, Lebanon
1 shared publicationCarole Kesrouani
Department of Pathology, Hotel-Dieu de France, Saint Joseph University of Beirut, Beirut, Lebanon
1 shared publication
Latest Publications
- 16 January 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 101, 102988
Unicentric retrospective study of gastroenteropancreatic neuroendocrine tumors: Updated epidemiological insights
- 16 January 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 101, 102988
Unicentric retrospective study of gastroenteropancreatic neuroendocrine tumors: Updated epidemiological insights
- 17 December 2025
- Published by Elsevier in The American Journal of Surgery
- Vol. 253, 116781
Multidimensional impacts of the Lebanese economic crisis on the management of acute cholecystitis
- 17 December 2025
- Published by Elsevier in The American Journal of Surgery
- Vol. 253, 116781
Multidimensional impacts of the Lebanese economic crisis on the management of acute cholecystitis
- 11 May 2023
- Published by Elsevier in Journal de Chirurgie Viscérale
- Vol. 160 (3) , S89-S93
Étendue du curage thérapeutique. Recommandations de l’AFCE (Association francophone de chirurgie endocrinienne) avec la SFE (Société française d’endocrinologie) et la SFMN (Société française de médecine nucléaire)
- 11 May 2023
- Published by Elsevier in Journal de Chirurgie Viscérale
- Vol. 160 (3) , S89-S93
Étendue du curage thérapeutique. Recommandations de l’AFCE (Association francophone de chirurgie endocrinienne) avec la SFE (Société française d’endocrinologie) et la SFMN (Société française de médecine nucléaire)
- 2 December 2019
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 19 (12) , 1089-1100
Surgical management of pancreatic neuroendocrine tumors: an introduction
Introduction: Neuroendocrine tumors of the pancreas (pNETs) represent only 1 to 2% of all pancreatic neoplasms. These tumors can be classified as functional or non-functional tumors; as sporadic or from a genetic origin; as neuroendocrine neoplasms or carcinoma. Over the last decade, diagnosis of pNETs has increased significantly mainly due to the widespread use of cross-sectional imaging. Those tumors are usually associated with a good prognosis. Surgery, the only curative option for those patients, should always be discussed, ideally in a multidisciplinary team setting. Areas covered: We discuss i), the preoperative management of pNETs and the importance of accurate diagnosis, localization, grading and staging with computed tomography, magnetic resonance imaging, endoscopic ultrasound and nuclear medicine imaging; ii), surgical indications and iii), the surgical approach (standard pancreatectomy vs pancreatic sparing surgery). Expert opinion: The treatment option of all patients presenting with pNETs should be discussed in a multidisciplinary team setting with surgeon’s experienced in both pancreatic surgery and neuroendocrine tumor management. A complete preoperative imaging assessment - morphological and functional - must be performed. Surgery is usually recommended for functional pNETs, non-functional pNETs >2cm (nf-pNETs) or for symptomatic nf-pNETs.
- 2 December 2019
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 19 (12) , 1089-1100
Surgical management of pancreatic neuroendocrine tumors: an introduction
Introduction: Neuroendocrine tumors of the pancreas (pNETs) represent only 1 to 2% of all pancreatic neoplasms. These tumors can be classified as functional or non-functional tumors; as sporadic or from a genetic origin; as neuroendocrine neoplasms or carcinoma. Over the last decade, diagnosis of pNETs has increased significantly mainly due to the widespread use of cross-sectional imaging. Those tumors are usually associated with a good prognosis. Surgery, the only curative option for those patients, should always be discussed, ideally in a multidisciplinary team setting. Areas covered: We discuss i), the preoperative management of pNETs and the importance of accurate diagnosis, localization, grading and staging with computed tomography, magnetic resonance imaging, endoscopic ultrasound and nuclear medicine imaging; ii), surgical indications and iii), the surgical approach (standard pancreatectomy vs pancreatic sparing surgery). Expert opinion: The treatment option of all patients presenting with pNETs should be discussed in a multidisciplinary team setting with surgeon’s experienced in both pancreatic surgery and neuroendocrine tumor management. A complete preoperative imaging assessment - morphological and functional - must be performed. Surgery is usually recommended for functional pNETs, non-functional pNETs >2cm (nf-pNETs) or for symptomatic nf-pNETs.
- Open Access
- 6 August 2019
- Published by Wiley in Journal of Obesity
- Vol. 2019, 1-6
Quality of Life before and after Sleeve Gastrectomy in Lebanese Population
Introduction. Obesity is increasing worldwide and in Lebanon with a negative impact on the quality of life. The primary objective of this study is to measure the quality of life in obese subjects before and after bariatric surgery, depending on age, sex, and degree of weight loss. A secondary objective is to determine the impact of bariatric surgery on comorbidities associated with obesity. Materials and methods. Patients undergoing laparoscopic sleeve gastrectomy for BMI ≥ 30 kg/m2 between August 2016 and April 2017 were included. Participants completed the Moorehead-Ardelt Quality of Life Questionnaire II (MA II) prior to operation and one year after. Statistical analysis was carried out using SPSS statistics version 20.0. Results. 75 patients participated in the study. The majority were women (75%), and the mean age was 36.3 years. The mean weight loss was 36.57 kg (16–76). Initially, the total MA II score was −0.33 ± 0.93. Postoperatively, it increased to 1.68 ± 0.62 (). All MA II parameters improved after surgery (), but this improvement was independent of age and sex. Improvement in self-esteem, physical activity, work performance, and sexual pleasure was influenced by the degree of weight loss (). All comorbidities associated with obesity regressed significantly after sleeve gastrectomy () with the exception of gastroesophageal reflux and varicose veins of the lower limbs. Conclusion. Sleeve gastrectomy improves quality of life and allows reduction of comorbidities.- 6 August 2019
- Published by Wiley in Journal of Obesity
- Vol. 2019, 1-6
Open AccessQuality of Life before and after Sleeve Gastrectomy in Lebanese Population
Introduction. Obesity is increasing worldwide and in Lebanon with a negative impact on the quality of life. The primary objective of this study is to measure the quality of life in obese subjects before and after bariatric surgery, depending on age, sex, and degree of weight loss. A secondary objective is to determine the impact of bariatric surgery on comorbidities associated with obesity. Materials and methods. Patients undergoing laparoscopic sleeve gastrectomy for BMI ≥ 30 kg/m2 between August 2016 and April 2017 were included. Participants completed the Moorehead-Ardelt Quality of Life Questionnaire II (MA II) prior to operation and one year after. Statistical analysis was carried out using SPSS statistics version 20.0. Results. 75 patients participated in the study. The majority were women (75%), and the mean age was 36.3 years. The mean weight loss was 36.57 kg (16–76). Initially, the total MA II score was −0.33 ± 0.93. Postoperatively, it increased to 1.68 ± 0.62 (). All MA II parameters improved after surgery (), but this improvement was independent of age and sex. Improvement in self-esteem, physical activity, work performance, and sexual pleasure was influenced by the degree of weight loss (). All comorbidities associated with obesity regressed significantly after sleeve gastrectomy () with the exception of gastroesophageal reflux and varicose veins of the lower limbs. Conclusion. Sleeve gastrectomy improves quality of life and allows reduction of comorbidities. - Open Access
- 18 September 2018
- Published by Wiley in Journal of Obesity
- Vol. 2018, 1-6
Resectional One Anastomosis Gastric Bypass/Mini Gastric Bypass as a Novel Option for Revision of Restrictive Procedures: Preliminary Results
Background. Revisional surgery is becoming a common and challenging practice in bariatric centers. The aim of this study was to evaluate resectional one anastomosis gastric bypass/mini gastric bypass (R-OAGB/MGB) as a revisional procedure. Methods. From January 2016 to February 2017, data on 21 consecutive patients undergoing R-OAGB/MGB for weight loss failure after primary restrictive procedures were prospectively collected and analysed. Results. Mean age was 39 ± 12 years (18–65), and 11 (52.3%) were women. The mean operative time was 96.4 ± 20.9 min (range, 122–80), and the mean postoperative stay was 47.8 ± 7.4 hours (range, 36–73). There were no deaths and no procedure-related complications. The mean body mass index (BMI) decreased from 42.9 ± 6.5 at the time of R-OAGB/MGB to 28.5 ± 4 at the 12-month follow-up. At that time point, the mean percentage of BMI loss (%EBL) and the mean percentage of total body weight loss (%TWL) reached 81.6 ± 0.17% and 35 ± 0.01%, respectively. Conclusion. R-OAGB/MGB was technically straightforward, effective, and safe in this at-surgical risk population. R-OAGB/MGB should be added to the armamentarium of revisional bariatric procedures considering its technical aspects and the potential advantage on weight loss.
- 18 September 2018
- Published by Wiley in Journal of Obesity
- Vol. 2018, 1-6
Open AccessResectional One Anastomosis Gastric Bypass/Mini Gastric Bypass as a Novel Option for Revision of Restrictive Procedures: Preliminary Results
Background. Revisional surgery is becoming a common and challenging practice in bariatric centers. The aim of this study was to evaluate resectional one anastomosis gastric bypass/mini gastric bypass (R-OAGB/MGB) as a revisional procedure. Methods. From January 2016 to February 2017, data on 21 consecutive patients undergoing R-OAGB/MGB for weight loss failure after primary restrictive procedures were prospectively collected and analysed. Results. Mean age was 39 ± 12 years (18–65), and 11 (52.3%) were women. The mean operative time was 96.4 ± 20.9 min (range, 122–80), and the mean postoperative stay was 47.8 ± 7.4 hours (range, 36–73). There were no deaths and no procedure-related complications. The mean body mass index (BMI) decreased from 42.9 ± 6.5 at the time of R-OAGB/MGB to 28.5 ± 4 at the 12-month follow-up. At that time point, the mean percentage of BMI loss (%EBL) and the mean percentage of total body weight loss (%TWL) reached 81.6 ± 0.17% and 35 ± 0.01%, respectively. Conclusion. R-OAGB/MGB was technically straightforward, effective, and safe in this at-surgical risk population. R-OAGB/MGB should be added to the armamentarium of revisional bariatric procedures considering its technical aspects and the potential advantage on weight loss.